Basic knowledge on leprosy: a short review by Lowe, Chamodika
MICROBIOLOGY | VIROLOGY | BIOLOGY
 
How to cite this article: Lowe C. Basic Knowledge on Leprosy: A Short Review. J Biomed Res Environ Sci. 2021 May 
21; 2(5): 345-349. doi: 10.37871/jbres1240, Article ID: JBRES1240
Leprosy is a chronic disease which is caused by the infection of Mycobacterium leprae 
bacterium and leads to neurological consequences. Regardless of its slow progressiveness, it is 
an exceptionally serious disease that is continuing to be a challenging health problem around the 
world. Early diagnosis and treatment is much important in controlling Leprosy. Already published 
articles and books on Leprosy have been studied and summarized in this review to present a basic 
understanding on pathogenesis, symptoms, diagnosis and treatment of Leprosy.
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INTRODUCTION
Leprosy, also called as Hansen’s disease is a chronic infectious disease endemic 
in tropical countries, that mainly leads to skin and peripheral nerves damage, is 
caused by the bacterium Mycobacterium leprae. According to WHO (World Health 
Organization) leprosy is clinically classifi ed as Paucibacillary (PB) if there are 
≤ 5 skin lesions and/ or involvement of one nerve trunk only, and Multibacillary 
(MB) if > 5 skin lesions and/ or >1 nerve trunk involved. It’s a curable disease but 
early detection is required to prevent transmission and disability [1]. The immune 
balance alterations between the host and the pathogen result in Leprosy Reactions 
which are acute incidences aff ecting the skin and nerves primarily. These reactions 
which are mainly responsible for the morbidity and neurological disabilities might 
take place during the disease course, while treating or after treatments. Leprosy 
reactions are classifi ed into two as Type 1 reaction (T1R/ Reversal/ downgrading) 
and Type 2 reaction (Erythema Nodosum Leprosum [ENL]) [1].
Type of organism
Causative organism, Mycobacterium leprae is a gram-positive, acid-fast-
staining, microaerophilic, non-spore-forming, nonmortile bacterium with a 
straight rod or slightly curved structure [2] (Figure 1).
Transmission
Leprosy is transmitted from an infected to a normal by close, prolonged contact. 
Transmission is mainly through nasal mucosa and sometimes skin erosions [3].
Other possible transmission paths are blood, breast milk, insect bites and 
vertical transmission [1].
PATHOGENESIS
Since M. leprae only infects human and is unable to culture in vitro, research 
into pathogenesis has been limited. Leprosy bacillus low virulence together with 
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eff ective host innate immunity may resist development of 
leprosy. M. leprae will be up taken by Dendritic Cells (DCs) and 
cause chemokines and cytokines to be produced, regulating 
infl ammation and infl uencing cause of T-helper1 or 
T-helper2 response from adaptive cell-mediated immunity. 
M. leprae infected monocyte-derived DCs downregulates 
expression of MHC (Major Histocompatibility Complex) 
class I and II. Production of CD40 ligand-associated 
interleukin-12 and MHC II is upregulated by M. leprae 
membrane antigens stimulated DCs suggesting suppression 
of T-cells and DCs interaction by live bacilli [4].
SYMPTOMS
Cardinal signs are macules which are hypopigmented/ 
erythematous with sensory loss, peripheral nerves that are 
thickened, adnexa loss at aff ected sites in a skin biopsy, 
positive acid-fast smear of skin [5]. In pure neural cases 
sensory or motor impairment of nerve/s can be the symptom.
Signs and Symptoms in reactional states
Type 1 reaction’s lesions are composed of the 
characteristic features erythema, hyperesthesia and edema, 
followed by scaling and at times ulceration. Neuritis and 
edema of extremities are seen often to be combined with 
this type of lesions [1]. Untreated acute neuritis will cause 
nerves to lose its function permanently leading to peripheral 
neuropathy [6].
Type 2 reaction results in subcutaneous infl ammatory 
nodules or erythema multiforme lesions distributed 
symmetrically in any region. Its general symptoms include 
malaise, arthralgia, myalgia, lymphadenomegaly, edema 
and fever. There can also be neuritis, uveitis, orchitis, 
arthritis, dactylitis and kidney or liver damage like internal 
involvement causing systemic disorders [1,6].
TREATMENT
Currently leprosy is treated with Multidrug Therapy 
(MDT) where a combination of dapsone, clofazimine and 
rifampin are used and the regimens decided depending on 
the type of leprosy. Ofl oxacin and minocycline is also used 
in treatment of Leprosy as second line drugs. For relapse 
assessment 10years follow-up is done. Some protection 
against M. leprae is also provided by BCG vaccine [2].
Treatment/management of reactions
Type 1 reaction is treated with the aim of easing pain, 
controlling acute infl ammation and reversing eye and nerve 
damage. MDT treatment should be continued while using 
oral corticosteroids like prednisolone to treat neuritis or 
moderately infl amed skin plagues [6].
Type 2 reaction’s treatment is mainly targeted at 
immunosuppression. High doses of corticosteroids such as 
prednisolone are used in treating more severe case while 
thalidomide is used to control type 2 reactions and prevent 
recurrences. Though clofazimine and pentoxifylline have a 
Figure 1 Mycobacterium leprae morphology [2].
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less eff ectiveness than both prednisolone and thalidomide, 
those have also been used in treating type 2 reaction. 
Two other drugs used here in treating are colchicine and 
chloroquine [6].
Deformity and it’s Management 
Leprosy causes neurological damages or neuropathy that 
leads to occurrence of lesions frequently. Hence, deformity 
and disability may result as secondary complications to this 
neuropathy through sensory impairment and loss of motor 
function [6].
Deformity and disability can be prevented by minimizing 
nerve damage through early identifi cation of weakening in 
nerve function and quick introduction of steroid therapy. 
Any further damages to a damaged site must be prevented 
by resting the site and using of antibiotics to treat any 
secondary infections. Patients must be educated on self-
examination, self-care, activities that can risk the damaged 
areas and protective footwear. Reconstructive surgery might 
be needed in contractures to improve function [6].
PREVENTION AND CONTROL
Leprosy can be prevented by avoiding prolong contact 
of an infected. Can be controlled making the public aware of 
leprosy early signs to reduce fear for leprosy and to detect it 
early, through anti-leprosy campaigns, mass media, posters 
and stickers. Medical staff s can be trained to reduce fear on 
leprosy and early diagnose aff ected. Skin camps can be set up 
to detect and treat minor cases of skin disorders [7].
EPIDEMIOLOGY
Introduction of MDT in early 1980s has been able to 
markedly decrease the prevalence of leprosy. Yet, it can 
still be observed endemic in tropical countries which 
are specially, developing or underdeveloped. 105 such 
endemic countries with a high number of cases have been 
identifi ed from Africa, America, Southeast Asia, Western 
Mediterranean and Eastern Pacifi c [1].
Though the elimination target set by WHO has been 
achieved by Sri-Lanka, there are still new leprosy cases 
(specially, child cases) being detected showing the presence 
of leprosy-bacilli in the environment. 
Graph
According to the trendline in Graph 1, number of leprosy 
cases tends be decreased with time. There’s an increment 
to be seen in 2nd quarters of 2014, 2015 and 2016. Highest 
number of incidences is seen in 2nd quarter of 2014 while 
lowest in 3rd quarter of 2015. 
In 2014 there are higher rates of cases mostly of children 
and that shows active transmission of the disease. Several 
programs such as “Media Seminar on World Leprosy Day” 
have been conducted in 2014 to modify lifestyles promoting 
good health. A national action plan has been prepared and 
has been implemented in several districts via a “model 
leprosy programme”. Community screening program has 
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Graph 1 Incidences of leprosy cases in Sri-Lanka during 2014-2017 [8].
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campaigns have been conducted to increase awareness on 
leprosy and identify patients [9].
All these have led to decrease in new cases in 2015. 
National action plan implemented in 2014 for some districts 
has been spread to island wide in 2015. Also the other 
campaigns have been continued and increased detection rate 
[10].
Major problem for disease controlling has been identifi ed 
as discrimination because of the disease and stigma. Main 
problem by 2016 has been higher MB leprosy cases and late 
presentation of child cases in high number. Anti-leprosy 
campaigns have been still continued [11].
As a prophylactic method of prevention pilot study on 
“Leprosy Postexposure Prophylaxis” (LPEP) was continued 
in 2017 together with other awareness programs [11].
CONVENTIONAL LABORATORY 
DIAGNOSIS
Gold standard for leprosy diagnosis is examination of 
paraffi  n embedded, neutral buff ered formalin fi xed sample 
of full-thickness skin biopsy taken from advancing margin 
of an active lesion. Here host response histological patterns 
can be identifi ed in sections stained with hematoxylin and 
eosin, acid-fast bacilli present in nerves can be identifi ed 
with carbol fuchsin satain modifi ed Fite-Faraco. Diff erential 
diagnosis is need where bacilli are rare [12].
Slit-skin smear is an ancillary procedure used to 
enumerate semi-quantitatively the acid fast organisms 
found in infected skin. This is used for follow ups in patients 
during treatments and after. Only experienced technicians 
will be able to give reliable results [12].
There are no serological tests for laboratory diagnosis 
of leprosy but several immunoassays are present to identify 
the antibodies against M. leprae’s PGL-1 (phenolic glycolipid 
1). But these don’t have a sensitivity and specifi city for a 
satisfactory level. Yet can be done for a low cost [12].
Lepromin test is a type of skin test used to test the ability 
in generation of granulomatous response for mycobacterial 
antigens. Response development can take time from 48-
72 hours to 4 weeks after heat-killed M. leprae is injected 
intradermally. This test is not specifi c to leprosy but a 
negative response is associated with leprosy while positive 
response associates with bacilli elimination in leprosy [12].
RECENT ADVANCES IN DIAGNOSIS
Polymerase Chain Reaction (PCR) is a technique used to 
identify leprosy by amplifying M. leprae-specifi c sequences 
and identifi es its fragments of DNA. PCR is also used in 
drug resistance development during treatment. 16S rRNA 
used for RNA analysis and reverse transcription -PCR have 
benefi ted in checking post treatment viability. Clinical and 
histopathological leprosy diagnosis is provided by PCR. It 
has a 100% specifi city and sensitivity ranging 34 – 80% in 
PB patients and greater than 90% in MB patients. But this 
method needs experts to carryout PCR and it is an expensive 
method [12].
Mass spectrometry- Skin lesion biopsies are used in this 
method to identify lipid markers [4].
Immunohistochemical Reaction - Monoclonal or 
polyclonal antibodies is used to detect antigens of leprosy 
bacilli in this method. Confi rmatory tests have to be done 
since false positive values and false negative valves can 
appear [1].
QUALITY CONTROL AND QUALITY 
ASSURANCE
The two parts of quality management are Quality control 
and quality assurance.  And it is also known as the most 
important fundermentals of laboratory measurements. 
When quality control fulfi ll the requirements of quality, 
quality assurance ensure whether the quality requirements 
are fulfi lled. The key quality systems is constitute with 
quality control and quality assurance. The guidance of quality 
assurance and control is the Standard Operation Procedure 
(SOP).  The quality system should be commensurate the 
business model and business objectives. The commitment 
and its active involvement of the top management are 
important to ensure the eff ectiveness and effi  ciency, 
suitability and adequacy of the quality systems [7].
The resources that are most important when improving 
quality is constitute by the company employees. Every unit 
employees are responsible to ensure the improvement and 
effi  ciency of their work. The motivating environment and 
the training should be provided by the top management 
towards the employees to improve their processes. At the 
end, the quality of the goods and services are a responsibility 
of everyone [7].
The main sections of quality assurance and quality 
control are Pre analytical phase, Analytical phase and Post 
analytical phase [7].
Storage, Sample Collection and Transport is included in 
Pre analytical phase. As important errors can be occurred 
in Pre analytical phase so to avoid errors and problems Pre 
analytical phase should have rigorous control measures [7].
Analytical phase is which sample analysis is occurring at 
a certain time. Here usually considered laboratory testing, 
diagnostic procedures, products and processes which 
ultimately give results. The errors can be reduced by the 
quality control internally and calibrating of the laboratory 
equipments [7].
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Making of the fi nal report is included in Post - analytical 
phase. Those reports must be issued to the relavent patients 
with the correct results as they are important when treating 
to the patients. And interpretation must also be done in this 
Post - analytical phase [7].
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